Key Takeaways
- Three licence types: Manufacturer’s licence (making/assembling/importing), wholesale distribution licence (selling/supplying), and parallel import licence (EEA-sourced medicines)
- Processing times: 90 working days for new applications, 30 working days for variations unless inspection required
- GMP and GDP compliance mandatory: Manufacturer’s licence holders need Good Manufacturing Practice; wholesale licence holders need Good Distribution Practice with regular MHRA inspections
- Windsor Framework changes: From 1 January 2025, MHRA licences all medicines across the UK; Parallel Distribution Notices no longer valid in Northern Ireland
- One RFI rule: MHRA issues only one Request for Further Information; applicants have 30 calendar days to respond before refusal
- Unlicensed medicines restricted: “Specials” can only be imported for special clinical needs, not for cost-saving or convenience
Understanding MHRA Pharmaceutical Import Licensing
Importing pharmaceutical products into the United Kingdom requires specific licences issued by the Medicines and Healthcare products Regulatory Agency (MHRA). The licensing regime ensures that all medicines entering the UK supply chain meet strict quality, safety, and efficacy standards. This guide covers the three main licence types, application procedures, and compliance requirements that UK importers must navigate.
The regulatory landscape changed significantly following the Windsor Framework implementation on 1 January 2025. The MHRA now licences all medicines across the entire UK, including Northern Ireland, and Parallel Distribution Notices (PDNs) that previously operated in Northern Ireland are no longer valid. Importers working across Great Britain and Northern Ireland must understand these unified requirements.
The licensing system distinguishes between three core activities: manufacturing (which includes importing finished medicines), wholesale distribution (selling or supplying medicines to entities other than patients), and parallel importing (bringing in medicines authorised in other EEA states). Each activity requires its own licence type, and many importers need multiple licences to operate legally. For a broader overview of UK import licensing requirements beyond pharmaceuticals, see our guide Do You Need an Import or Export Licence?.
Manufacturer’s Licence: When You Need It and How to Apply
A manufacturer’s licence is required if you are making, assembling, or importing human medicines in the UK. The MHRA defines “importing” in this context as bringing finished medicines into the UK from outside the country, even if you are not physically manufacturing them yourself. This licence covers the full range of activities from primary manufacturing through to packaging and labelling.
The application process begins with submitting form MLX to the MHRA. Processing time for new manufacturer’s licence applications is 90 working days from receipt of a complete application. The MHRA operates a “one RFI” rule: they will issue only one Request for Further Information during the assessment. Applicants have 30 calendar days to address all issues raised; failure to respond adequately within this timeframe results in automatic refusal.
Good Manufacturing Practice (GMP) compliance is mandatory for all manufacturer’s licence holders. The MHRA conducts regular inspections of licensed sites to verify ongoing GMP compliance. Inspection frequency depends on the risk profile of the medicines handled and the compliance history of the site. New licence holders can expect an initial inspection within the first year of operation.
The annual fee structure for manufacturer’s licences varies based on the number of manufacturing sites covered and income generated from wholesale activities. The MHRA publishes detailed fee schedules on GOV.UK, with charges typically ranging from £3,000 to £15,000 annually depending on scope. Importers operating multiple sites should budget accordingly and factor in inspection costs for each location.
For companies importing finished medicines without any repackaging or relabelling, the manufacturer’s licence still applies. This is a common point of confusion — the act of importing medicines for commercial supply triggers the licensing requirement regardless of whether physical manufacturing occurs. Companies acting solely as importers should ensure their licence application clearly specifies the scope of activities to avoid unnecessary inspection burdens.
Wholesale Distribution Licence Requirements
A wholesale distribution licence is required if you sell or supply medicines to anyone other than the patient using the medicine. This covers the entire distribution chain from manufacturer to pharmacy, hospital, or other healthcare provider. Importers who also distribute medicines they have imported need both a manufacturer’s licence (for the import activity) and a wholesale distribution licence (for onward supply).
The application uses form WDL and follows similar processing timelines to manufacturer’s licences: 90 working days for new applications. Good Distribution Practice (GDP) compliance is mandatory, with the MHRA conducting regular inspections of licensed premises. GDP covers storage conditions, temperature monitoring, stock rotation, transportation arrangements, and record-keeping systems.
Temperature-controlled storage is a critical GDP requirement for pharmaceutical products. Most medicines require storage between 15°C and 25°C, with some requiring refrigeration at 2°C to 8°C. Wholesale licence holders must demonstrate validated cold chain systems, continuous temperature monitoring, and documented procedures for handling temperature excursions. The MHRA inspectors routinely check calibration records for monitoring equipment and review temperature logs for the preceding 12 months.
Record-keeping requirements under GDP are extensive. Wholesale licence holders must maintain records of all transactions including supplier details, customer details, batch numbers, quantities, and dates. These records must be retained for at least five years and be immediately accessible for MHRA inspection. Electronic systems are acceptable provided they meet data integrity requirements and have appropriate backup arrangements.
The annual fee for wholesale distribution licences follows a similar structure to manufacturer’s licences, scaled by the number of sites and wholesale income. Companies operating multiple distribution centres should note that each site requires inspection and may incur separate fees. Some operators structure their operations to minimise the number of licensed sites, using a single central warehouse with satellite locations operating under the same licence where permissible.
Parallel Import Licensing Scheme
Parallel import licences allow medicines authorised in EEA Member States to be marketed in the UK if they have no therapeutic difference from the UK-equivalent product. This scheme enables importers to source medicines from lower-priced European markets and supply them in the UK, creating price competition while maintaining regulatory oversight.
The MHRA recognises three parallel import licence categories with different assessment requirements. Simple applications involve medicines from a common origin with the UK product — these receive the fastest assessment. Standard applications cover products with no common origin but without complex differences. Complex applications involve new excipients, different active ingredient routes, controlled release formulations, sterile product differences, influenza vaccines, metered dose inhalers, or powders for inhalation — these require the most extensive assessment.
Parallel import licences are valid for five years from the date of grant. Renewal applications should be submitted at least six months before expiry to avoid supply disruption. The MHRA maintains a public register of parallel import licences, which importers should check before submitting applications to avoid duplicating existing authorisations.
The Windsor Framework changes affected parallel importing significantly. From 1 January 2025, Parallel Distribution Notices that previously operated in Northern Ireland are no longer valid. All parallel imports into any part of the UK now require MHRA parallel import licences. Importers who previously relied on PDNs for Northern Ireland supply must transition to the full parallel import licensing regime.
Falsified Medicines Directive requirements apply to parallel imported medicines. Importers must ensure safety features (unique identifier and anti-tamper device) are present and functional throughout the supply chain. The MHRA has published specific guidance on compliance with FMD requirements for parallel importers, including procedures for verifying and decommissioning unique identifiers.
Unlicensed Medicines: Specials and Exemptions
Unlicensed medicines can be imported under specific exemptions, but the rules are narrow and strictly enforced. The term “Specials” refers to unlicensed medicines supplied to meet the special clinical needs of individual patients. Importers of Specials must notify the MHRA and can be objected to if quality concerns exist. These exemptions exist for genuine clinical need, not for cost-saving or convenience.
Clinical trial Investigational Medicinal Products (IMPs) can be imported under clinical trial authorisations. The sponsor of the clinical trial holds responsibility for ensuring IMP quality and compliance with GMP standards equivalent to EU requirements. Importers acting on behalf of trial sponsors should verify that the sponsor holds appropriate authorisations before handling any IMP shipments.
The Early Access to Medicines Scheme (EAMS) provides a route for patients with life-threatening or seriously debilitating conditions to access unlicensed medicines before marketing authorisation. EAMS products can be imported under specific arrangements coordinated between the manufacturer, MHRA, and NHS. Commercial importers should not attempt to handle EAMS products without explicit MHRA authorisation.
Regulation 174 of the Human Medicines Regulations 2012 provides exemptions for small quantities of unlicensed medicines imported in response to unsolicited orders from healthcare professionals. The exemption applies only where the medicine is supplied to meet the special clinical needs of an identifiable patient group. Importers relying on Regulation 174 must maintain detailed records of orders received and supplies made, as the MHRA may request these during inspections.
NHS Specialist Pharmacy Service guidance makes clear that unlicensed medicines cannot be supplied simply because they are cheaper than licensed alternatives. The “special clinical need” test requires that no licensed alternative exists that would meet the patient’s needs. Importers who cannot demonstrate this distinction risk enforcement action including licence revocation and criminal prosecution.
Application Process, Fees, and Timelines
The MHRA application process for all pharmaceutical import licences follows a standard sequence. Pre-application advice is available for £500 and can help identify potential issues before formal submission. Many applicants find this investment worthwhile, particularly for first-time applications or complex multi-site operations.
Form submission must be completed through the MHRA’s online portal. Paper applications are no longer accepted. The portal requires detailed information about the applicant company, proposed activities, site locations, key personnel, and quality management systems. Applicants should prepare this information in advance to avoid incomplete submissions that trigger RFI delays.
Like other regulated import categories, pharmaceutical imports require careful attention to customs procedures. For a complete overview of UK import processes, see our Customs Clearance UK step-by-step guide.
The 90-working-day processing clock starts only when the MHRA receives a complete application. Incomplete applications are held until all required information is provided, at which point the clock restarts. The one RFI rule means applicants have a single opportunity to address any gaps — thorough preparation before submission is essential.
Fees are payable at application and annually thereafter. Current fee schedules are published on GOV.UK and updated each April. Budget for application fees ranging from £1,500 to £5,000 depending on licence type, plus annual fees from £3,000 to £15,000. Multi-site operations should calculate fees for each location separately.
Variation applications to modify existing licences process faster than new applications — typically 30 working days for administrative changes. Variations that require inspection (such as adding new sites or changing scope of activities) revert to the 90-working-day timeline. Importers planning expansion should factor these timelines into commercial planning.
Compliance and Enforcement
MHRA compliance monitoring is ongoing throughout the licence period. Licensed operators should expect unannounced inspections at least every two years, with higher-risk operations inspected more frequently. Inspection findings are categorised as critical, major, or other deficiencies. Critical or major deficiencies can trigger licence suspension or revocation if not remediated promptly.
Enforcement powers available to the MHRA include licence suspension, licence revocation, seizure of medicines, and criminal prosecution. Serious breaches involving patient safety risks can result in immediate suspension pending investigation. The MHRA publishes enforcement actions on its website, and adverse findings can damage commercial relationships with suppliers and customers.
Record-keeping is a common inspection finding. Importers should maintain comprehensive records of all licence applications, correspondence with the MHRA, inspection reports, and remediation actions. A dedicated regulatory file accessible to all relevant staff helps ensure consistent compliance and demonstrates a quality culture to inspectors.
Staff training is another critical compliance area. All personnel involved in licensed activities must receive appropriate training in GMP or GDP as applicable, with training records maintained and refreshed annually. The MHRA routinely interviews staff during inspections to verify that training is effective and understood at the operational level.
For importers working with third-party logistics providers, clear contractual arrangements defining regulatory responsibilities are essential. The licence holder retains ultimate responsibility for compliance even when activities are outsourced. Service agreements should specify GDP requirements, audit rights, and notification procedures for any quality incidents.
Pharmaceutical importers should also be aware of other UK regulatory regimes affecting imported goods, such as chemical compliance under UK REACH, which shares similar documentation and due diligence requirements.
Frequently Asked Questions
How long does an MHRA pharmaceutical import licence take to process? New applications take 90 working days from receipt of a complete application. Variations without inspection take 30 working days. The MHRA operates a one RFI rule with 30 calendar days to respond before refusal.
What is the difference between a manufacturer’s licence and a wholesale distribution licence? A manufacturer’s licence covers making, assembling, or importing medicines. A wholesale distribution licence covers selling or supplying medicines to entities other than patients. Importers who also distribute need both licences.
Can I import unlicensed medicines for cost savings? No. Unlicensed medicine exemptions apply only for special clinical needs where no licensed alternative exists. Importing unlicensed medicines purely for cost-saving is not permitted and risks enforcement action.
Do I need separate licences for Great Britain and Northern Ireland? No. Following the Windsor Framework from 1 January 2025, the MHRA licences all medicines across the entire UK. A single licence covers operations in England, Scotland, Wales, and Northern Ireland.
How often does the MHRA inspect licensed premises? Expect inspections at least every two years. Higher-risk operations or those with previous compliance issues may be inspected more frequently. Unannounced inspections are standard practice.
What happens if my parallel import licence expires? Parallel import licences are valid for five years. Submit renewal applications at least six months before expiry to avoid supply disruption. Expired licences cannot be used to supply medicines.